22.10-1.00-4.33%
11:39:42 AMBTT
Plus500. 80% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Wednesday morning 07/17/2024 the Hims & Hers Health Inc Registered Shs -A- share started trading at the price of $22.82.Compared to the closing price on Tuesday 07/16/2024 on BTT of $23.10, this is a drop of 1.21%.There are 206.41 M shares outstanding in Hims & Hers Health Inc Registered Shs -A-, which values the company at $4.92 B.
Is Hims & Hers Health stock a Buy, Sell or Hold?
Hims & Hers Health stock has received a consensus rating of buy. The average rating score is and is based on 16 buy ratings, 13 hold ratings, and 2 sell ratings.What was the 52-week low for Hims & Hers Health stock?
The low in the last 52 weeks of Hims & Hers Health stock was 5.67. According to the current price, Hims & Hers Health is 389.77% away from the 52-week low.What was the 52-week high for Hims & Hers Health stock?
The high in the last 52 weeks of Hims & Hers Health stock was 25.74. According to the current price, Hims & Hers Health is 85.86% away from the 52-week high.What are analysts forecasts for Hims & Hers Health stock?
The 31 analysts offering price forecasts for Hims & Hers Health have a median target of 14.23, with a high estimate of 26.00 and a low estimate of 4.00. The median estimate represents a 155.35 difference from the last price of 22.10.Hims Hers Health A Stock Snapshot
22.09
Bid
500.00
Bid Size
22.11
Ask
100.00
Ask Size
7/17/2024
Date
11:39 AM
Time
188,165.00
Volume
23.10
Prev. Close
22.82
Open
206.41 M
Number of Shares
21.97
Day Low
23.33
Day High
22.10
5.67
52 Week Low
25.74
52 Week High
22.10
0.00
Dividend in USD
73.07
Free Float in %
-0.11
EPS in USD
1.61
Book Value per Share in USD
0.35
Cash Flow per Share in USD
Hims & Hers Health NewsMore News
Benzinga
Should You Keep Chemed Stock in Your Portfolio Now?
Chemed Corporation (NYSE: CHE)is primed to grow in the upcoming quarters, backed by the promising prospects of the VITAS business. The company is set to capitalize on the positive trends of the global Hospice industry. Moreover, sound financial stability appears encouraging.
Benzinga
Quest Diagnostics Set to Acquire OhioHealth's Lab Services
Quest Diagnostics (NYSE: DGX) recently announced a definitive agreement to purchase the select assets of OhioHealth's outreach laboratory services business. The transaction will expand access to the company's cost-effective and advanced laboratory services in Ohio.
InvestorPlace
3 Stocks Poised to 10X in the Next 5 Years
Benzinga
3 Companies Set to Positively Surprise this Earnings Season
Earnings season has arrived, with Friday's big bank results shifting the period into a much higher gear. The period looks to be positive, with earnings growth expected to be strong, again underpinned by a strong forecasted showing from the Tech sector.
Benzinga
Historical Prices for Hims & Hers Health
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Hims & Hers Health Analyst Data
Total Analysts: 31
Buy Ratings: 16 Neutral Ratings: 13 Sell Ratings: 2
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 4.00 Median: 14.23 Highest: 26.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Hims & Hers Health Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/11/24 | Piper Sandler | Maintained Hold | $18 | neutral | ||
| 06/27/24 | Jefferies & Company Inc. | Maintained Hold | $23 | neutral | ||
| 06/13/24 | Bank of America Merrill Lynch | Maintained Buy | $26 | gut | ||
| 06/03/24 | Bank of America Merrill Lynch | Maintained Buy | $22 | gut | ||
| 05/22/24 | Capital Depesche | Maintained Buy | $24 | gut | ||
| 05/22/24 | Citigroup Corp. | Downgraded to Hold | $20 | neutral | ||
| 05/07/24 | Deutsche Bank | Maintained Hold | $16 | neutral | ||
| 05/07/24 | Piper Sandler | Maintained Hold | $13 | neutral | ||
| 04/16/24 | Jefferies & Company Inc. | Downgraded to Hold | $15 | neutral | ||
| 04/10/24 | Capital Depesche | Maintained Buy | $20 | gut | ||
| 02/27/24 | Guggenheim | Maintained Buy | $17 | gut | ||
| 02/27/24 | Citigroup Corp. | Maintained Buy | $16 | gut | ||
| 02/27/24 | Piper Sandler | Maintained Hold | $11 | neutral | ||
| 08/08/23 | Credit Suisse | Maintained Buy | $14 | gut | ||
| 05/30/23 | Piper Sandler | Maintained Hold | $11 | neutral | ||
| 05/09/23 | Bank of America Merrill Lynch | Maintained Buy | $15 | gut | ||
| 05/09/23 | Piper Sandler | Maintained Hold | $12 | neutral | ||
| 04/27/23 | Guggenheim | Maintained Buy | $18 | gut | ||
| 04/26/23 | Piper Sandler | Maintained Hold | $11 | neutral | ||
| 04/11/23 | Baird Patrick & Co | Maintained Hold | $10 | neutral | ||
| 03/01/23 | Credit Suisse | Maintained Buy | $14 | gut | ||
| 02/28/23 | Guggenheim | Maintained Buy | $15 | gut | ||
| 02/28/23 | Citigroup Corp. | Maintained Buy | $14 | gut | ||
| 02/28/23 | Piper Sandler | Maintained Hold | $10 | neutral | ||
| 02/28/23 | Bank of America Merrill Lynch | Maintained Buy | $13.5 | gut | ||
| 02/09/23 | Jefferies & Company Inc. | Upgraded to Buy | $11 | gut | ||
| 11/08/22 | Bank of America Merrill Lynch | Upgraded to Buy | $8.5 | gut | ||
| 11/08/22 | SVB Leerink | Upgraded to Hold | neutral | |||
| 10/17/22 | Piper Sandler | Downgraded to Hold | $6 | neutral | ||
| 08/10/22 | Credit Suisse | Maintained Buy | $8 | gut | ||
| 08/09/22 | SVB Leerink | Maintained Sell | $5 | schlecht | ||
| 07/15/22 | SVB Leerink | Maintained Sell | $4 | schlecht |
Hims & Hers Health Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 1,249 | 1,606 | 1,930 | 2,222 | 2,253 |
| Dividend | 0.00 | 0.00 | 0.00 | - | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | - | - |
| EPS | 0.17 | 0.48 | 0.77 | 0.93 | 1.04 |
| P/E Ratio | 134.65 | 47.29 | 29.66 | 24.53 | 22.01 |
| EBIT | 38 | 78 | 139 | 133 | 194 |
| EBITDA | 137 | 199 | 273 | 350 | 403 |
| Net Profit | 38 | 70 | 99 | 102 | 143 |
| Net Profit Adjusted | 123 | 183 | 233 | 266 | 262 |
| Pre-Tax Profit | 48 | 89 | 150 | 153 | 277 |
| Net Profit (Adjusted) | 53 | 79 | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | 0.16 | 0.31 | 0.46 | 0.63 | 0.67 |
| Gross Income | 1,041 | 1,346 | 1,613 | 1,869 | 1,865 |
| Cash Flow from Investing | -54 | -44 | -66 | -66 | -121 |
| Cash Flow from Operations | 148 | 205 | 290 | 368 | 412 |
| Cash Flow from Financing | -54 | -44 | -66 | -66 | -121 |
| Cash Flow per Share | 0.65 | 0.86 | - | - | - |
| Free Cash Flow | 94 | 161 | 269 | 363 | - |
| Free Cash Flow per Share | 0.49 | 0.76 | - | - | - |
| Book Value per Share | 1.96 | 2.72 | - | - | - |
| Net Debt | -217 | -418 | - | - | - |
| Research & Development Exp. | 62 | 81 | 96 | 118 | 125 |
| Capital Expenditure | 28 | 27 | 37 | 43 | 85 |
| Selling, General & Admin. Exp. | 295 | 358 | 356 | 438 | 480 |
| Shareholder’s Equity | 437 | 589 | 757 | 1,026 | 1,102 |
| Total Assets | 557 | 732 | 962 | 1,275 | 1,273 |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 7 | 7 | 7 | 7 | 11 |
| Average Estimate | 0.040 USD | 0.034 USD | 0.042 USD | 0.170 USD | 0.484 USD |
| Year Ago | -0.034 USD | -0.036 USD | 0.006 USD | -0.113 USD | - |
| Publish Date | 8/5/2024 | 11/4/2024 | 3/3/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 12 | 12 | 12 | 13 | 13 |
| Average Estimate | 300 USD | 325 USD | 349 USD | 1,249 USD | 1,606 USD |
| Year Ago | 208 USD | 227 USD | 247 USD | 872 USD | - |
| Publish Date | 8/5/2024 | 11/4/2024 | 3/3/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Sales | 872.00 | 526.92 | 271.88 | 0.00 | 0.00 |
| Change of sales in % | 65.49 | 93.81 | - | - | - |
| Gross profit on sales | 705.43 | 401.25 | 200.42 | 0.00 | 0.00 |
| Gross profit on sales change in % | 75.81 | 100.20 | - | - | - |
| Operating income | -33.46 | -68.48 | -115.04 | -4.79 | -0.71 |
| Operating income change in % | 51.13 | 40.48 | -2,300.85 | -574.82 | - |
| Income before tax | -21.57 | -65.71 | -110.80 | -40.27 | 1.15 |
| Income before tax change in % | 67.17 | 40.69 | -175.12 | - | - |
| Income after tax | -23.55 | -65.68 | -107.66 | -40.27 | 1.15 |
| Income after tax change in % | 64.15 | 38.99 | -167.34 | - | - |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total liabilities | 97.16 | 54.60 | 85.97 | 59.66 | 8.17 |
| Long-term liabilities per share | 0.04 | 0.03 | 0.03 | 2.18 | 0.29 |
| Equity | 344.03 | 311.74 | 334.62 | 145.97 | 196.59 |
| Equity change in % | 10.36 | -6.84 | 129.24 | -25.75 | - |
| Balance sheet total | 441.19 | 366.34 | 420.59 | 205.63 | 204.77 |
| Balance sheet total change in % | 20.43 | -12.90 | 104.53 | 0.42 | - |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Sales per share | 4.17 | 2.58 | 1.46 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | 216.78 |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | 216.78 |
| P/E ratio (year end quote) | - | - | - | - | 216.78 |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 77.98 | 85.10 | 79.56 | 70.99 | 96.01 |
| Debt ratio in % | 22.02 | 14.90 | 20.44 | 29.01 | 3.99 |
Hims & Hers Health Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Baird Melissa | 07/08/2024 | 17,625.00 | 585,800.00 | 20.42 | Sell | No |
| Boughton Soleil | 07/08/2024 | 2,335.00 | 169,144.00 | 20.28 | Sell | No |
| Baird Melissa | 07/08/2024 | 17,625.00 | 603,425.00 | 0.40 | Buy | No |
| Baird Melissa | 07/07/2024 | 17,625.00 | 585,800.00 | 20.90 | Sell | No |
| Baird Melissa | 07/07/2024 | 17,625.00 | 603,425.00 | 0.40 | Buy | No |
| Baird Melissa | 07/04/2024 | 17,625.00 | 585,800.00 | 20.51 | Sell | No |
| Baird Melissa | 07/04/2024 | 17,625.00 | 603,425.00 | 0.40 | Buy | No |
| Dudum Andrew | 07/02/2024 | 144,444.00 | 1,021,534.00 | 20.69 | Sell | No |
| Dudum Andrew | 07/02/2024 | 94,444.00 | 127,946.00 | 20.75 | Sell | No |
| Dudum Andrew | 07/02/2024 | 94,444.00 | 33,502.00 | 20.74 | Sell | No |
| Dudum Andrew | 07/02/2024 | 188,888.00 | 222,390.00 | 2.43 | Buy | No |
| Okupe Oluyemi | 06/24/2024 | 11,546.00 | 177,449.00 | 22.21 | Sell | No |
| Boughton Soleil | 06/24/2024 | 2,335.00 | 171,479.00 | 22.18 | Sell | No |
| Chi Michael | 06/23/2024 | 17,303.00 | 185,326.00 | 22.07 | Sell | No |
| Chi Michael | 06/23/2024 | 17,303.00 | 202,629.00 | 5.01 | Buy | No |
| Chi Michael | 06/19/2024 | 7,500.00 | 185,326.00 | 24.50 | Sell | No |
| Dudum Andrew | 06/19/2024 | 18,314.00 | 60,943.00 | 22.35 | Sell | No |
| Dudum Andrew | 06/19/2024 | 700.00 | 33,502.00 | 24.31 | Sell | No |
| Dudum Andrew | 06/19/2024 | 26,741.00 | 34,202.00 | 23.37 | Sell | No |
| Chi Michael | 06/19/2024 | 7,500.00 | 192,826.00 | 13.90 | Buy | No |
| Becklund Irene | 06/17/2024 | 13,241.00 | 2,913.00 | 23.59 | Sell | No |
| Chi Michael | 06/17/2024 | 25,549.00 | 185,326.00 | 23.59 | Sell | No |
| Becklund Irene | 06/16/2024 | 472.00 | 16,154.00 | 24.10 | Sell | No |
| Becklund Irene | 06/16/2024 | 472.00 | 16,626.00 | 9.41 | Buy | No |
| Carroll Patrick Harrison | 06/13/2024 | 3,811.00 | 202,763.00 | 23.75 | Sell | No |
Hims Hers Health A Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Hims & Hers Health Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2022 | Hims & Hers Health Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2021 | Hims & Hers Health Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2020 | Hims & Hers Health Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2019 | Hims & Hers Health Inc Registered Shs -A- | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Hims & Hers Health Inc Registered Shs -A- Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.040 USD | Q2 2024 Earnings Release | 08/05/2024 |
| Earnings Report | 0.034 USD | Q3 2024 Earnings Release | 11/04/2024 |
| Earnings Report | 0.042 USD | Q4 2024 Earnings Release | 03/03/2025 |
| Earnings Report | 0.089 USD | Q1 2025 Earnings Release | 05/12/2025 |
Hims & Hers Health Inc Registered Shs -A- Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 06/06/2024 |
Hims & Hers Health Profile
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Hims & Hers Health Shareholder
| Owner | in % |
|---|---|
| Freefloat | 73.07 |
| The Vanguard Group, Inc. | 6.87 |
| Vanguard Group, Inc. (Subfiler) | 6.76 |
| Forerunner Ventures LLC | 4.73 |
| NewView HMS SPV Partners LLC | 4.68 |
| Jack Abraham | 4.52 |
| Institutional Venture Partners | 3.36 |
| Marshall Wace LLP | 2.73 |
| Redpoint Ventures | 2.46 |
| Redpoint Ventures | 2.46 |
| Samlyn Capital LLC | 2.36 |
| BlackRock Fund Advisors | 2.31 |
| Vanguard Total Stock Market ETF | 2.18 |
| BlackRock Institutional Trust Co. NA | 2.10 |
| Newview Capital Partners I LLC | 1.91 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
